Back to News
Market Impact: 0.2
GeNeuro Secures European Patent For GNK-301 In ALS
Source: Nasdaq
Healthcare & BiotechPatents & Intellectual Property
NRx Pharmaceuticals subsidiary GeNeuro received European Patent EP 3 570 878 B1 for GNK-301, a novel monoclonal antibody targeting the HERV-K envelope protein. The patent strengthens intellectual-property protection for GNK-301's potential therapeutic development, though the article provides no clinical, commercial, or financial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
NRXP0.55
More News
- Bausch Health raises 2026 outlook as third-quarter adjusted earnings surge 53%
- This hospice services stock is outperforming the S&P 500. Jefferies sees more gains ahead
- Waters’ new AI tool targets one of the pharmaceutical industry’s most tedious tasks
- Biotechs buck a sluggish IPO market, but investors should tread warily
- Wedbush cuts Geron stock price target to $5 on study halt
- Needham initiates Clover Health stock with buy on cohort economics